Pfizer Inc. ( PFE, Financial) rose to prominence during the Covid-19 pandemic for its rapid development of a vaccine and ...

Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday ...

Pfizer remains an attractive capital return play with a 10X P/E ratio, despite concerns about post-COVID revenue declines.

Although it has been plagued by multiple issues, including falling sales with lower demand for its Covid-19 products, and an ...

Pfizer is removing its Oxbryta pill for sickle cell disease from all markets globally due to safety risks, including deaths.

Pfizer Inc. (NYSE:PFE) rose to prominence during the Covid-19 pandemic for its rapid development of a vaccine and antiviral therapy, establishing a household name in the process. As the pandemic ...

Along with the annual flu vaccine, the new COVID-19 vaccine formulation is now widely available in Minnesota. It comes at a ...

Pfizer Canada says Health Canada has approved its updated COVID-19 vaccine that protects against one of the most recently ...

BioNTech's updated COVID-19 vaccine on Tuesday, marking its third authorization of vaccine formulations that protect against ...

Pfizer stock (NYSE: PFE) is trading at about $30 per share, not far from the lows seen in recent years. Could the stock rise by over 2x in value over the next few years? Does this sound a bit ...

Pfizer-BioNTech's updated vaccine to protect against a recently circulating COVID-19 variant is authorized, Health Canada said on Tuesday. The federal vaccine and treatment portal lists ...